

\$200,000,000

INCYTE GENOMICS, INC.

5.5% CONVERTIBLE SUBORDINATED NOTES DUE 2007
 and
 SHARES OF COMMON STOCK
 ISSUABLE UPON CONVERSION OF THE NOTES

This prospectus supplement relates to the resale by the holders of 5.5% convertible subordinated notes due 2007 of Incyte Genomics, Inc. and the shares of common stock issuable upon conversion of the notes.

This prospectus supplement should be read in conjunction with the prospectus dated August 2, 2000, which is to be delivered with this prospectus supplement.

The information in the table appearing under the heading "Selling Securityholders" in the prospectus is supplemented and superseded in part by the information appearing in the table below:

Name -----	Principal Amount of Notes Beneficially Owned and Offered(1)(3) -----	Common Stock Issuable Upon Conversion of the Notes(1)(2)(3) -----	Common Stock Offered(1)(2)(3) -----	Common Stock Owned After Completion of the Offering(1) -----
DEUTSCHE BANC ALEX BROWN INC	\$3,948,000	58,558	58,558	—

(1) Amounts indicated may be in excess of the total amount registered due to sales or transactions exempt from the registration requirements of the Securities Act of 1933 since the date on which selling securityholders provided information to us regarding their notes.

None of the selling securityholders listed above nor any of their affiliates, officers, directors or principal equity holders has held any position or office or has had any material relationship with us within the past three years.

(2) Amounts indicated reflect a 2-1 stock split effected in the form of a stock dividend on August 31, 2000.

(3) Amounts indicated supercede the prospectus dated August 2, 2000 and all prior prospectus supplements thereto with respect to the amounts owned by Deutsche Banc Alex Brown Inc.

Investing in the notes and our common stock involves a high degree of risk. You should carefully read and consider the "Risk Factors" beginning on page 3 of the prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the prospectus. Any representation to the contrary is a criminal offense.